Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 1720 生達. Please read: https://finlab.finance/en/setup?stock=1720

No install, open FinLab Studio

1720

生達 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

strong quality, discounted valuation, no active signal today.

This page refreshes daily after the close. Add 生達 to your watchlist to track signal changes on your next visit.

Is 生達 a buy? Fundamentals and valuation first

Top-tier profitability.Operating margin beats ~85% of the market. Latest quarterly ROE ≈ 3.2%.
Valuation is low.PE is in the 12th market percentile; within its own history, PE is around the 9th percentile.
Foreign investors are net buying.Foreign 20-day net flow ≈ 8.2% of volume (net buy).

Chip flow

Neutral +0.05

BearishNeutralBullish

Institutional rotation, concentration steady — neutral

Institutional rotation, concentration steady — neutral
元富-大昌 holds 995 lots
sellers have 186 lots left, ~75 sessions to clear

Window from 2026-01-17 · Price +2% · branches to 2026-06-17· TDCC to 2026-06-12

Largest holder 元富-大昌 has accumulated 995 lots since the start (sold 1%), holding.
Main distributor 凱基-台北 peaked at 139 lots, has sold 83%, 24 left, paused recently.
TDCC big holders (absolute) >1000-lot holders -1.01pp, mid holders +0, retail +0.02pp — little change.
Foreign hedge-desk net short Net short -529 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).

Branch inventory reconstruction

Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.

Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.

Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.

Accumulating

元富-大昌第一金元大-屏東民生元大-內湖民權臺銀統一-城中

Distributing

凱基-台北摩根大通群益金鼎永豐金-屏東玉山-景美台新-台南

Desks

own scale

中國信託-永康新加坡商瑞銀國票-敦北法人台灣摩根士丹利

Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline

Branch details Unit: lots

Accumulating

元富-大昌 +995

sold 1%
第一金 +406

sold 0%
元大-屏東民生 +212

sold 4%
元大-內湖民權 +125

sold 0%· still adding
臺銀 +123

sold 15%
統一-城中 +122

sold 0%

Distributing

凱基-台北 24 left

sold 83%· paused recently
摩根大通 31 left

sold 75%· paused recently
群益金鼎 76 left

sold 25%· ~29 sessions to clear
永豐金-屏東 26 left

sold 73%· ~4 sessions to clear
玉山-景美 37 left

sold 36%· ~23 sessions to clear
台新-台南 11 left

sold 79%· paused recently

Desks

中國信託-永康 -1,055

unclassified
新加坡商瑞銀 -416

hedge desk · will cover
國票-敦北法人 -266

unclassified
台灣摩根士丹利 -253

hedge desk · will cover

Still selling 186 lots ~75 sessions to bottom at most

Recent buy/sell force +554 absorbed / -133 sold buyers slightly ahead

Hedge-desk net short -456 lots potential cover-buying, not selling pressure

TDCC big holders · absolute-holding cross-check

>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

0-20 +18.2% Now

20-40 +6.3%

40-60 +7.5%

60-80 +10.8%

80-100 -13.2%

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20 You are here	1370	+18.2%	+15.7%	86.4%	-0.8%
20-40	583	+6.3%	+4.1%	67.9%	-9%
40-60	577	+7.5%	+3.4%	69.2%	-8.5%
60-80	196	+10.8%	+2.5%	54.6%	-7.2%
80-100	293	-13.2%	-16.4%	11.3%	-21.3%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 11.61, at the 8.7th percentile of its own history (0-20 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation

Momentum

Cheap (own-history bottom 1/3)

Mid

Expensive (own-history top 1/3)

60-day momentum up

Now

+9%

Win rate 78.3% Excess +0.7%

991d

+6.5%

Win rate 52.1% Excess +0.2%

562d

-0.4%

Win rate 30.6% Excess -8.2%

229d

60-day momentum down

+8.4%

Win rate 75.5% Excess -1.9%

856d

+1.3%

Win rate 59.8% Excess -7.3%

323d

-1.9%

Win rate 34.5% Excess -9.4%

177d

Currently in “Cheap (own-history bottom 1/3) × 60-day momentum up”: across 991 historical days, 120-day forward avg gained 9%, win rate 78.3%, beat the market by 0.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

30 times historically; 60-day forward avg +2.67%, win rate 46.7%, beating the market by -1.62 pts on average.

Monthly revenue YoY ≥ 20% (from filing deadline)

Pending

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

39 times historically; 60-day forward avg +12.2%, win rate 71.9%, beating the market by +7.6 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

68 times historically; 60-day forward avg +3.32%, win rate 55.2%, beating the market by -0.03 pts on average.

What does 生達 do? Company profile

生技醫療業；西藥製造業、學名藥、原料藥、保健食品與藥妝通路相關台灣證券交易所上市

Overview

1720 對應證券為生達化學製藥股份有限公司，為台灣證券交易所上市普通股，英文簡稱 S.C.P.C.。公司成立於 1967/06/30，1993/08/26 公開發行，1995/12/12 於台灣證券交易所掛牌上市。總部與主要廠區位於台南市新營區，公開資訊常見地址為台南市新營區土庫里土庫 6-20 號，另二廠地址為台南市新營區開元路 154 號，並設有台北、台中、高雄辦事處及越南、菲律賓、泰國、中國、薩摩亞等海外據點。董事長與總經理均為范滋庭。實收資本額約新台幣 17.87 億元，已發行普通股約 178,696,089 股。公司 2025 年合併營收約新台幣 70.23 億元，歸屬母公司業主淨利約新台幣 9.28 億元，EPS 5.19 元。員工規模方面，官方 2024 永續揭露截至 2024 年底公司總人數 829 人；就業平台與徵才資料另顯示約 850 至 874 人，口徑可能包含不同期間或集團/個體差異。主要股東依可查資料包含范進財、范滋彬、范黃美榮、范滋庭、鄭森豪、葉翠雯、盈生投資、財團法人范道南文教基金會、員工福儲信託專戶及外資保管帳戶等；其中部分資料來自生泰年報揭露生達作為法人股東之主要股東，非生達公司年報逐字來源。

Business

生達是以學名藥為核心的綜合製藥集團，業務涵蓋人用西藥製劑、原料藥、保健食品、醫療/保健產品零售與通路，以及部分加工、研發、授權、代理新藥與 CDMO/CMO。公司產品線包含心血管、代謝、皮膚外用、泌尿生殖、抗感染、呼吸、肌肉骨骼、消化、神經、循環等西藥製劑，也經營保健食品品牌與代理商品。2025 年合併收入按產品/勞務別約為：人用藥銷售收入 32.15 億元，占約 45.8%；食品銷售收入 22.09 億元，占約 31.4%；原料藥銷售收入 13.21 億元，占約 18.8%；加工收入 0.02 億元以下；其他 2.77 億元，占約 3.9%。地區別以台灣為主，2025 年台灣收入約 54.98 億元，日本約 5.82 億元，其他地區約 9.43 億元；財報揭露無單一客戶收入達合併營收 10% 以上。商業模式為自有品牌藥品與保健品研發、生產、銷售，透過醫院、診所、藥局、賣場、食品公司及連鎖藥妝通路銷售；海外則採自有持證、技術移轉、授權當地合作夥伴、原廠代理、CDMO/CMO、與原料藥廠策略聯盟等多元模式。集團垂直整合特徵明顯：生泰提供原料藥能力，生展提供微生物發酵、功效素材與保健營養食品能力，佑全提供連鎖藥局與藥妝通路，和耀生技支援高技術/專利障礙學名藥及 505(b)2 研發。

Outlook 2025–2028

2025 至 2028 展望以「從台灣走向國際化」及「從學名藥廠進化至 Better than Generics」為主軸。台灣市場方面，公司 2026 年預計上市 6 件新品，包含膀胱過動症首發藥 1 件、CNS 2 件、糖尿病 1 件、胃腸 1 件、怯痰藥 1 件；國內成長動能來自新藥/新學名藥上市、慢性病與高齡化用藥需求、保健食品與連鎖通路，以及集團內製劑、原料藥、保健食品與通路整合。日本市場方面，公司已與日本大廠進行 CDMO 合作，2026 法說資料列示日本 2 件品項持續出貨、2 件 PMDA 審核中、4 件在研中，並積極洽談 CMO/新藥代理；日本 AG 與 Bio-AG 藥價制度調整可能讓具自主研發、成本控制與穩定供應能力的學名藥廠取得機會。中國市場方面，公司策略為自有品牌與技轉並行、CDMO、擴大合作品項與藥企家數，已累積自有持證 3 件、技轉領證 3 件、一致性評價審查中 1 件、在研中 3 件，並強調「台灣生產、進口中國」差異化定位。美國與其他市場方面，公司聚焦專利挑戰、自有專利布局、多區域招商、API 策略合作與 CDMO/CMO；2026 法說資料列示美國 2 件品項持續出貨、2 件在研中並招商。主要風險包含：台灣健保藥價調降與價格壓力、中國集採與一致性評價造成低價競爭、美國學名藥價格侵蝕與 FDA 資料完整性要求、日本審查與藥價制度變動、匯率波動、原料藥供應與成本、研發送件時程不確定、CDMO/授權案量能與客戶集中度變化、海外法規與品質查廠風險。2027 至 2028 的量化營收或獲利目標未在可查公開資料中明確揭露，因此此區間只能以產品管線、海外送件、CDMO/CMO 進度與產業趨勢作方向性判斷。

Supply Chain

Upstream

生泰合成工業股份有限公司 1777 生達轉投資事業與集團原料藥供應鏈核心，專注高品質原料藥研發、製造及銷售；生達法說資料亦強調與生泰/API 垂直整合以強化成本與供應優勢。
生展生物科技股份有限公司 8279 生達轉投資子公司，提供微生物發酵、專利功效素材、保健營養食品與部分原料藥相關能力，屬保健食品與生技原料上游/集團協同來源。
和耀生技股份有限公司未上市研發型關係企業，聚焦高技術或專利障礙學名藥、罕病用藥及 505(b)2 新藥之藥物研究與處方設計，屬研發與製劑技術上游支援。
生達策略聯盟原料藥廠商公司法說資料多次提及與原料藥廠深度合作、策略聯盟以穩定供應並控制成本，但未完整揭露全部合作廠商名稱。

Downstream

佑全藥品股份有限公司 6929 生達關係企業，經營佑全保健藥妝、健康人生藥局及札幌藥粧等連鎖通路，服務藥局、診所、醫院與大型連鎖店，屬集團下游通路。
全國醫院、診所、藥局、賣場及食品公司 2025 合併財報查核事項揭露，生達集團人用藥及保健食品內銷客戶包括全國各地醫院、診所、藥局、賣場及食品公司，客戶眾多且分散；非單一上市櫃公司。
日本、中國、東南亞、韓國等海外合作夥伴與藥廠海外採授權、技轉、共同持證、CDMO/CMO、代理與當地合作夥伴銷售模式；多數合作對象未在公開資料中完整具名。

Competitors

永信藥品工業股份有限公司 1716 台灣上市製藥公司，學名藥、處方藥與保健相關產品，為國內製劑同業。
中國化學製藥股份有限公司 1701 台灣上市製藥公司，西藥製劑與醫藥相關產品，為國內老牌製藥競爭者。
杏輝藥品工業股份有限公司 1734 台灣上市製藥公司，涵蓋處方藥、OTC、外用藥及保健品等，與生達在藥品製劑市場重疊。
美時化學製藥股份有限公司 1795 台灣上市製藥公司，聚焦特殊學名藥與國際市場，與生達在學名藥國際化方向具可比性。
保瑞藥業股份有限公司 6472 台灣上市製藥與 CDMO 公司，近年積極國際併購與委託製造，與生達在製劑、CDMO/CMO 與國際市場競爭。
中化合成生技股份有限公司 1762 台灣上市原料藥與醫藥中間體廠，屬 API 供應鏈同業，亦可能在原料藥市場與生達集團生泰競爭。
台耀化學股份有限公司 4746 台灣上市原料藥與高活性 API 廠，屬原料藥及 CDMO 相關同業。
神隆股份有限公司 1789 台灣上市原料藥公司，聚焦高活性原料藥，為 API 供應鏈同業。
葡萄王生技股份有限公司 1707 台灣上市保健食品與生技公司，與生達食品/保健營養品業務有部分競爭。
大江生醫股份有限公司 8436 台灣上櫃保健食品與生技代工公司，與生達集團保健食品、功效素材及代工相關業務有部分競爭。

Sources（19）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
Excess return is measured against the TAIEX total-return index (dividends included).
Valuation regime and percentile stats use an expanding own-history window (no future data).
Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.